PubMed Health⌕ Search

Biomedical subjects

J S Pryor

Publications and source records attributed to J S Pryor.

At least 19 recordsLinked to original sources

Effect of arterial-portal glucose gradients and phloridzin on bile glucose levels in perfused rat liver.

1. Bivascular perfused rat liver was used to study the effects of hepatic artery-portal vein glucose gradients and the effects of phloridzin on bile glucose levels. 2. Bile glucose levels were examined when glucose concentrations in the hepatic artery (HA) and portal vein (PV) inflows were equal. When the concentration of perfusate glucose was 10 mM, bile glucose remained stable at less than 0.075 mM; when perfusate glucose exceeded approximately 16.0 mM, bile glucose increased rapidly; when 1.6 microM phloridzin and 10.0 mM glucose were co-infused, phloridzin entered rapidly into bile and settled at a steady-state concentration of 0.45 +/- 0.04 mM, and bile glucose increased to 3.75 +/- 0.14 mM. 3. During perfusion of HA-PV glucose gradients such that HA glucose was higher than that in the sinusoids, bile glucose levels were increased compared with their levels when HA glucose was equivalent to that in the sinusoids. The converse was also demonstrated. 4. The results regarding phloridzin-sensitive glucose transport in the biliary tree of the rat were consistent with those documented in vivo. The finding that bile glucose levels altered in a manner parallel to that of the HA, although the total inflow remained unchanged, strongly indicated that HA glucose level, rather than that of the PV, performs an important role in control of bile glucose levels.

Animals↗

Potassium-mediated stimulation of hepatic glycogenolysis.

Increased extracellular potassium concentrations ([K+]o) stimulated transient increases in glucose release and 45Ca2+ washout in the perfused rat liver. Stimulated glucose release had a K0.5 of about 26 mM for [K+]o, was not desensitized by successive infusion intervals of increased [K+]o, was not affected by altering the direction of perfusion, was absolutely dependent on the presence of [Ca2+]o, and was blocked by 2 mM cobalt or 10 microM verapamil. The increase in 45Ca2+ washout resulting from increased [K+]o also was blocked by 2 mM cobalt or 10 microM verapamil. Inhibitors of vascular tone (nitroprusside, atriopeptin II), arachidonic acid metabolism (indomethacin, nordihydroguaiaretic acid), and alpha- or beta-adrenergic or muscarinic nerve stimulation/secretion (phentolamine, propranolol, atropine) were unable to inhibit the [K+]o-stimulated glucose release. ATP, ADP, and AMP concentrations in tissue freeze-clamped 2 min after the onset of infusion of 50 mM K+ were not significantly different from control tissue. Glucose release from freshly isolated suspensions or primary cultured monolayers of hepatocytes or from liver slices, all of which responded to glucagon or phenylephrine, did not respond to increased [K+]o. The results indicate that glycogenolysis stimulated by depolarizing gradients of K+ is dependent on an intact perfused vasculature and may be mediated by potential-sensitive Ca2+ channels present in the vascular endothelium of the liver.

Animals↗

Effects of haemodialysis on taste and thirst.

Fifteen patients undergoing haemodialysis tasted soup varying in salt concentration and apple puree varying in sucrose concentration, immediately before and after dialysis. Matched controls tasted the same foods with a similar interval between tastings. The samples were rated for intensity, and on a relative-to-ideal scale. For the salt, the slopes of the functions plotted against log (concentration) were higher after dialysis than before, whilst the most preferred concentration was lower. There were no effects found for the sweetness ratings or for the controls. Likewise there were no overall differences in the ratings between the patients and controls. Thirst was found to increase on dialysis, and there was a trend of this being higher for the patients than for the controls. The reduction in preferences for salt by dialysis would make compliance with a reduced salt diet easier, but the increase in thirst would make compliance with reduced fluid intake more difficult.

Adolescent↗

Effects of haemodialysis on taste for salt in relation to changes in blood constituents.

Taste sensitivity and preference for sodium chloride in bread and pea soup were assessed before and after haemodialysis in 12 female chronic renal failure patients. Blood samples were also taken pre- and post-dialysis and analysed for zinc, sodium and renin. The patients demonstrated an increased sensitivity to, and decreased preference for, sodium chloride in both bread and pea soup following dialysis. These taste changes were found to correlate with pre- to post-dialysis changes in the zinc levels in the blood. Patients receiving a more severely sodium-restricted diet showed a greater sensitivity to the taste of sodium chloride in the foods tested. Renin levels dropped in all patients following dialysis, the size of the change correlating with the size of the change in body weight.

Adult↗

Changes in salt taste in dialysis and their relationship to blood constituents.

Taste sensitivity for sodium chloride in solution and sensitivity and preference for sodium chloride in bread were measured in 14 male patients undergoing hemodialysis. There was an increase in sensitivity to salt taste following dialysis only when assessed using the bread samples. Patients on a lower sodium diet were more sensitive to salt taste in bread. Although the taste changes were not related to the decreases in serum sodium or to copper, greater increases in sensitivity were related to greater increases in serum zinc during dialysis.

Adult↗

Evidence for adrenergic control of transcellular calcium distribution in liver.

Free Ca2+ concentration and 45Ca flux were measured in the perfusate and bile of the perfused rat liver. With a perfusate Ca2+ concentration of 1 mM, the bile concentration was 0.35 mM. The ratio of 45Ca in bile to that in blood increased from 0.3 to 0.6 over 90 min of perfusion. Both verapamil and adrenaline (via alpha-adrenergic receptors) increased the 45Ca bile/perfusate ratio to 0.8. Adrenaline infusion increased the bile Ca2+ concentration to 0.8 mM. This decreased to 0.35 mM after the infusion was stopped.

Animals↗

Lack of binding of glyceraldehyde-3-phosphate dehydrogenase to erythrocyte membranes under in vivo conditions.

A filtration method is described for separating membrane-free cytoplasm from concentrated erythrocyte haemolysates. The method has been used to assess glyceraldehyde-3-phosphate dehydrogenase binding to erythrocyte membranes. The relative amounts of glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase in the cytoplasm (either oxygenated or deoxygenated) indicate there is no detectable binding of glyceraldehyde-3-phosphate dehydrogenase to the membranes under physiological conditions.

Aerobiosis↗

Glyceraldehyde-3-phosphate dehydrogenase release from erythrocytes during haemolysis. No evidence for substantial binding of the enzyme to the membrane in the intact cell.

Glyceraldehyde-3-phosphate dehydrogenase (G3PDH, EC 1.2.1.12) release from haemolysing erythrocytes, and its redistribution between free and membrane-bound states, were studied with a new type of rapid-mixing filtration apparatus. The apparatus is described. The results indicate that the rate of G3PDH appearance in filtrates is determined not only by the enzyme redistribution but also by the kinetics of haemolysis. We have quantified the extent of haemolysis as a function of time, by measuring the amounts of filterable K+ and lactate dehydrogenase. These are cytoplasmic components that are not membrane-bound. When we correct for incomplete haemolysis, extrapolation to zero times indicates that very little G3PDH is membrane-bound in the intact cell.

Blood↗

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

Mevinolin reduces cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. The safety and effectiveness of this agent was evaluated in a double-blind, placebo-controlled study in 59 healthy men (serum cholesterol 3.88--7.76 mmol/liter) in five centers. Subjects maintained their usual diet and activities. Doses of 6.25, 12.5, 25, or 50 mg twice daily for 4 wk produced mean reductions of total serum cholesterol fo 23--27% [vs. placebo (4%), P less than 0.01]. Mean low density lipoprotein cholesterol fell 35--45%, while high density lipoprotein and very low density lipoprotein cholesterol, and triglycerides were not significantly affected. Mean apolipoprotein B fell 27--34%. 50 mg was not significantly more effective than 6.25 mg. Mevinolin was generally well tolerated, and no serious clinical or laboratory abnormalities occurred. One subject (12.5 mg) was withdrawn because of abdominal pain and diarrhea. These results suggest that if long-term safety can be demonstrated, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase are likely to prove useful in the treatment of hypercholesterolemia.

Adolescent↗

Captopril for refractory hypertension in patients with chronic renal failure and renal transplantation.

The converting-enzyme inhibitor, captopril, was given to ten patients with refractory severe hypertension of renal origin: 6 patients had chronic renal failure, 3 patients had hypertension following renal transplantation, and one patient had hypertension and congestive cardiac failure. Control of blood pressure was achieved with doses from 78 to 400 mg/day. Severe hyperkalaemia occurred in one patients, ageusia (dose dependent) in another, and one patients withdrew from treatment because of nausea.

Adolescent↗

Budd Chiari syndrome from myosarcoma of right atrium.

A 50-year-old man presented with abdominal pain followed by marked liver and renal dysfunction. Although liver scan appearances were not diagnostic, at laparotomy a tense, enlarged liver was found with thrombosis of the inferior vena cava. Despite full supportive measures the patient died within a month of laparotomy. Subsequent necropsy confirmed the diagnosis of Budd Chiari syndrome and revealed the primary cause to be a myosarcoma of the right atrium, an occurrence hitherto unreported.

Budd-Chiari Syndrome↗